Moderna Inc. (NASDAQ:MRNA) is one of the Ten stocks with notable resilience.
Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to end at $49.06 apiece, as investors positioned their portfolios ahead of their participation in a conference next week.
In a notice to investors, Moderna Inc. (NASDAQ:MRNA) said it will join the 47th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 9. Investors are expected to stay tuned for updates from the company on the progress of its portfolio.
Photo by MA Arkhipov on Shutterstock
In addition to Goldman Sachs, the company is also expected to hold its annual shareholder meeting called Science Day on June 25, 2026, where it will showcase its latest advances in mRNA platform science, basic research and pipeline developments.
In other news, Moderna Inc. (NASDAQ:MRNA) presented, along with Merck, five-year data for Intismeran Autogene in combination with Keytruda in patients with high-risk stage 3 and 4 melanoma at the recently concluded 2026 ASCO annual meeting.
According to Moderna Inc. (NASDAQ:MRNA), patients who received Intismeran Autogene in combination with Keytruda successfully reduced cancer recurrence and risk of death by 49 percent, as well as its ability to spread to distant parts of the body by 59 percent.
While we recognize MRNA’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 33 stocks that should double in 3 years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.